Paclitaxel, cisplatin, 5-fluorouracil and radiotherapy in the management of advanced squamous cell carcinoma of the head and neck: a phase II trial

Marco Merlano; Elvio G Russi; Gianmauro Numico; Ida Colantonio; Ornella Garrone; Antonio Pelissero; Cristina Granetto; Milena Gasco; Gianna Di Costanzo; Abdelhamid Heouaine; Riccardo Vigna Taglianti; Marco Cipolat

doi:10.1016/j.radonc.2004.11.007

Paclitaxel, cisplatin, 5-fluorouracil and radiotherapy in the management of advanced squamous cell carcinoma of the head and neck: a phase II trial

Radiother Oncol. 2005 May;75(2):193-6. doi: 10.1016/j.radonc.2004.11.007. Epub 2004 Dec 9.

Authors

Marco Merlano¹, Elvio G Russi, Gianmauro Numico, Ida Colantonio, Ornella Garrone, Antonio Pelissero, Cristina Granetto, Milena Gasco, Gianna Di Costanzo, Abdelhamid Heouaine, Riccardo Vigna Taglianti, Marco Cipolat

Affiliation

¹ Department of Medical Oncology, S. Croce General Hospital, Cuneo, Italy. mcmerlano@tiscali.it

PMID: 16086909
DOI: 10.1016/j.radonc.2004.11.007

Abstract

Aim of the present study was to test, activity and toxicity of a rapidly alternating chemoradiation (paclitaxel based) in 31 patients with unresectable, locally advanced or recurrent after surgery, head and neck cancer. Three-year overall survival and progression-free survival were 61.4 and 73.7%, respectively. Main side effects remain a major problem.

Publication types

Clinical Trial
Clinical Trial, Phase II

MeSH terms

Adult
Aged
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Carcinoma, Squamous Cell / drug therapy*
Carcinoma, Squamous Cell / pathology
Carcinoma, Squamous Cell / radiotherapy*
Cisplatin / administration & dosage
Combined Modality Therapy
Female
Fluorouracil / administration & dosage
Head and Neck Neoplasms / drug therapy*
Head and Neck Neoplasms / pathology
Head and Neck Neoplasms / radiotherapy*
Humans
Male
Middle Aged
Paclitaxel / administration & dosage
Treatment Outcome

Substances

Paclitaxel
Cisplatin
Fluorouracil